Dietzschold B, Kao M, Zheng Y M, Chen Z Y, Maul G, Fu Z F, Rupprecht C E, Koprowski H
Wistar Institute of Anatomy and Biology, Philadelphia, PA 19109.
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7252-6. doi: 10.1073/pnas.89.15.7252.
The in vitro biological activities of several rabies virus-neutralizing monoclonal antibodies (mAbs) were compared with their ability to prevent a lethal rabies virus encephalomyelitis. The protective activity of a particular mAb in vivo did not correlate with its virus-neutralizing activity in vitro; rather it was related to the mAb's ability to inhibit virus spread from cell to cell and to restrict rabies virus RNA transcription. Since treatment of rabies virus-infected cells with virus-neutralizing mAbs results in an endocytosis of the antibody, we hypothesize that an antibody may exert its inhibitory activity even after uptake by the cell. Post-exposure treatment of rats with a mAb that inhibited both virus spread and virus RNA transcription in vitro resulted in viral clearance from the central nervous system and protected the animals against a lethal rabies virus infection.
将几种狂犬病病毒中和单克隆抗体(mAb)的体外生物学活性与其预防致死性狂犬病病毒脑脊髓炎的能力进行了比较。特定mAb在体内的保护活性与其体外病毒中和活性不相关;相反,它与mAb抑制病毒在细胞间传播以及限制狂犬病病毒RNA转录的能力有关。由于用病毒中和mAb处理狂犬病病毒感染的细胞会导致抗体的内吞作用,我们推测即使抗体被细胞摄取后也可能发挥其抑制活性。用一种在体外能抑制病毒传播和病毒RNA转录的mAb对大鼠进行暴露后治疗,可使病毒从中枢神经系统清除,并保护动物免受致死性狂犬病病毒感染。